Avrobio -based biotech start-up Avrobio has raised $60m in a series B funding round col-led by Cormorant Asset Management and Surveyor Capital . Massachusetts has developed a gene therapy for Fabry disease, a lysosomal storage disorder which allows fatty deposits to build up in the body. It has no bearing on ex vivo lentiviral gene therapy.” Clinical trials last autumn saw patients' enzyme levels match those without the disease, with no side-effects after 2016 of treatment. The latest funding, which followed a $25m series A in last autumn , will be used to begin a phase two trial of the gene therapy AVR -RD-01.
Avrobio -based biotech start-up Avrobio has raised $60m in a series B funding round col-led by Cormorant Asset Management and Surveyor Capital . Massachusetts has developed a gene therapy for Fabry disease, a lysosomal storage disorder which allows fatty deposits to build up in the body. Clinical trials last autumn saw patients' enzyme levels match those without the disease, with no side-effects after 2016 of treatment. The latest funding, which followed a $25m series A in last autumn , will be used to begin a phase two trial of the gene therapy AVR -RD-01.